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Summary The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein whose expression
is important in the regulation of breast cancer cell growth. The relationship between EGFR status (determined
by an immunocytochemical assay) and various prognostic factors was investigated in 164 primary breast
cancers. Overall 56% of tumours were EGFR-positive and the expression of EGFR was unrelated to axillary
node status, tumour size and histological grade; and it was poorly associated with the tumour proliferative
activity measured by Ki-67 immuno-cytochemistry. The relapse-free survival (RFS) probability at 3-years was
significantly worse for patients with EGFR positive tumours (P = 0.003) and for those whose Ki-67 score was
>7.5% (P = 0.0027), as well as in patients with axillary node involvement (P = 0.01) and with poorly
differentiated tumours (P = 0.04). Immunocytochemical determination of EGFR and cell kinetics gave super-
imposable prognostic information for predicting RFS with odds ratios of 3.51, when evaluated singly. In our
series of patients EGFR, Ki-67 and node status retain their prognostic value concerning RFS in multivariate
analysis. The 3-year probability of overall survival (OS) was significantly better in node-negative patients
(P = 0.04) and was similar in EGFR-positive and negative patients.
In conclusion, EGFR status appears to be a significant and independent indicator of recurrence in human
breast cancer and the concomitant measurement of the tumour proliferative activity seems to improve the
selection of patients with different risks of recurrence.
At present axillary node involvement is the single best prog-
nostic factor in early breast cancer and is used frequently to
identify patients eligible for adjuvant treatment (McGuire,
1987; Fisher et al., 1968). Node status alone, however, does
not fully account for the varied outcome of the patients and
we are still unable to accurately predict the clinical course of
all patients. Furthermore, node status is not useful in selec-
ting the best treatment for each case (McGuire, 1987;
Blamey, 1989). There is thus an increasing need to define new
biological markers, associated with tumour aggressiveness, to
allow separation of groups of patients with slowly growing
tumours who might need no adjuvant therapy from those at
high risk.
Recent studies have reported that overexpression of the
epidermal growth factor receptor (EGFR) was associated
both with enhanced metastatic potential of some breast
cancer cell lines (Fitzpatrick et al., 1984; Roos et al., 1986)
and with high risk of early recurrence and death in some
clinical studies (Sainsbury et al., 1987; Macias et al., 1987;
Toi et al., 1991). Although there is no unequivocal evidence
that amplification of EGFR is the initial transforming event
in human breast carcinoma (Stoscheck & King, 1986; Heldin
& Westermark, 1984), an autocrine mechanism is considered
as an important step for the independent growth of tumour
cells (Lippman et al., 1986; Salomon et al., 1984). Conse-
quently the prognostic significance of EGFR status needs
further investigation (Bonadonna, 1990).
There is also increasing evidence that the measurement of
cell kinetics is also of considerable prognostic value (Tubiana
et al., 1984; Hedley et al., 1987; Silvestrini et al., 1985). The
development of monoclonal antibodies which recognises
antigens associated with tumour proliferative activity has
allowed its determination by in situ immunocytochemical
assays (Chan et al., 1983; Freeman et al., 1988). These are
both easy and rapid to perform and have some technical
advantages over other methods (Gasparini et al., 1989). The
Ki-67 monoclonal antibody, which is expressed by pro-
liferating cells only (Gerdes et al., 1984), was reported by our
group (Gasparini et al., 1989) and others (Charpin et al.,
1988; Isola et al., 1990), to be associated with known features
of tumour aggressiveness (i.e.: node involvement, high his-
tologic grade, aneuploidy and absence of steroid hormone
receptors).
In the present report we have analysed the relationship
between EGFR and the proportion of proliferative cells
detected by the monoclonal antibody Ki-67 and conventional
features of tumour aggressiveness in order to define their
prognostic significance in a series of patients with stage I-II
breast cancer.
Patients and methods
One hundred and seventy patients with operable breast car-
cinoma who underwent surgery at the St. Bortolo Regional
Medical Center of Vicenza from 1987 to 1989 were included
in the present prospective study.
The eligibility criteria for the inclusion of women with
primary breast cancer in this study were: (1) primary T,-T3;
No 2; MO, unilateral breast cancer; (2) a tumour specimen
obtained between 1987 and 1989 at the time of mastectomy
with analysis of EGFR, Growth Fraction (GR) by Ki-67 and
the main clinico-pathologic characteristics (menopausal
status, pathologic tumour size, node status, and histologic
grade); (3) no other primary cancer. All patients were staged
according to the UICC-TNM classification.
One hundred and sixty-four of the 170 eligible patients
were evaluable, six being lost to follow-up. Of the 164
evaluable patients, 90 underwent radical mastectomy and 74
had quadrantectomy plus radiotherapy. Adjuvant treatments
were administered to all node-positive patients according to
the recommendations of the 2nd NIH Consensus Develop-
ment Conference on Adjuvant Chemotherapy and Endocrine
Therapy for Breast Cancer (1985). Cyclophosphamide,
methotrexate and 5-fluorouracil (CMF) chemotherapy was
administered for eight cycles every 21 days in pre-peri-
menopausal and in ER-negative postmenopausal patients (51
cases); tamoxifen 10 mg t.i.d was given orally daily for 3
years in ER-positive postmenopausal patients (30 cases).
Patients who underwent radical mastectomy who were found
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to have more than seven axillary nodes involved, received
subsequent adjuvant radiotherapy (32 cases).
Patient characteristics are shown in Table I. At the time of
this report, the median follow-up was 36 months (range 12 to
42 months).
Tumour size was recorded as the largest diameter of the
tumour at the time of trimming the fresh specimens.
For histologic determination the surgical specimens were
first evaluated by frozen section and then fixed in buffered
formalin for 24 h at 20°C, dehydrated through graded
ethanol and paraffin embedded at 56°C for 30 min. Tumours
were classified by histologic type according to the criteria of
the National Surgical Adjuvant Breast Project (Fisher et al.,
1975).
Histologic grading was according to the criteria of Bloom
and Richardson (1957). All identifiable lymph-nodes in the
axillary specimens were examined by light microscopy after
haematoxylin and eosin staining (median cleared = 16).
Biochemical hormonal receptor assay was performed in snap-
frozen tumour samples according to the E.O.R.T.C. method
(1973). Samples with apparent affinity constants >0.56 x
109 mol 1` and > 10 f.mol mg-' of cytosol protein were con-
sidered oestrogen receptor (OER) or progesterone receptor
(PgR)-positive. EGFR was analysed with the monoclonal
antibody EGFR1, isolated by Waterfield et al. (1982) (clone
EGFR1 Amersham International Lab, UK). Immunocyto-
chemical staining was carried out by an avidin-biotin com-
plex immunoperoxidase method (Hsu et al., 1981). Serial
sections used for cryostatic intraoperative diagnosis were
used for immunocytochemistry and the analysis was per-
formed as previously described (Bevilacqua et al., 1990).
Tumours were classified as EGFR-positive (at least 5% of
cells with membrane staining) or negative, adopting the
criteria already published (Bevilacqua et al., 1990). Epidermal
growth factor receptor was used as a dichotonomous variable
and scored as either positive or negative. Intensity of staining
was not considered. Adopting this classification 92 tumours
(56%) were EGFR positive while 72 were EGFR negative.
The commercially available Dakopatts Kit was used for the
GF analysis (Dakopatts Ltd, UK). This employs the IgGI
mouse Moab Ki-67, produced by Gerdes et al. (Gerdes et al.,
1984).
Table I Clinico-pathologic characterstics of the patients
Total evaluable
Median age yrs (range)
Menopausal status
premenopausal
perimenopausal
postmenopausal
Tumour size
pTl
pT2
pT3
Node status
negative
positive
1-3
4-7
8-10
>10
Grading
I
II
III
Growth fraction score
High (>7.5%)
Low (<7.5%)
aOestrogen receptor status
negative
positive
aProgesterone receptor status
negative
positive
aAvailable in 150 patients.
N° ofcases
164/170
56 (31-71)
47
14
103
93
67
4
83
81
46
17
9
9
10
76
78
83
81
67
84
86
65
95
28.5
8.5
63.0
56.5
41.0
2.5
50.5
49.5
6.0
46.5
47.5
51
49
44
56
57
43
The determination of Ki-67 staining was performed as
previously reported (Gasparini et al., 1989). Briefly: the
immunocytochemical assay was performed on frozen sections
(5 um) fixed in cold acetone (- 10C), washed in 0.01 M
phosphate-buffered saline (PBS). Primary antibody was
diluted 1:50 for 60 min and tested in biotinylated horse
anti-mouse Ig for 30 min (Vector Lab, Burlingame, CA,
USA) and avidin-biotinylated horseradish peroxidase com-
plex for 30 min (Vector Lab, Burlingame, CA, USA). A
diamino-benzidine hydrogen peroxide substrate was em-
ployed as chromogen. The number of cells with nuclear
staining was determined in each slide by two observers
independently, counting the number of positive nuclei and
the total number of nuclei in 12 fields ( x 20 objective, Zeiss
photomicroscope). We considered positive those nuclei with
diffuse brown nuclear staining.
Since tumours appeared to be heterogeneous for Ki-67
labelling, the determination of GF count was done in the
areas of the section with the most intense labelling rate (i.e.
at the 'hot spot'). Intensity of staining was not considered.
An average of 1,000 nuclei per section were counted. Growth
fraction was used as a dichotomous variable, and the median
value of 7.5% was used as cut-off point to discriminate
slowly versus rapidly proliferating tumours. Adopting this
criterion, 81 tumours (49%) were classified as slowly pro-
liferating (Ki-67 scores <7.5%) while 83 (51%) as rapidly
proliferating tumours (Ki-67 scores >7.5%).
All patients were followed-up postoperatively and physical
examination was performed monthly during the treatment
with adjuvant CMF or the first 6 months of adjuvant tamox-
ifen in node-positive cases. In these women, after completion
of the adjuvant programme, as well as in all node-negative
women, physical examination was performed every 4 months
during the first 3 years following surgery. Six patients were
lost to follow-up and were not included in the analysis of
prognostic factors. Primary treatment failure was defined as
the first documented evidence of new disease manifestation(s)
in loco-regional area(s), distant site(s), contralateral breast,
or a combination of the above. Any new disease involvement
was assessed by clinical, radiological and, wherever feasible,
histologic examination of the site(s) of first relapse.
Statistics
The association between EGFR and the clinico-pathologic
variables was evaluated by Chi-square (X2) test. The agreement
between EGFR and GF was analysed by the K coefficient
(Table II). The patterns of overall survival (OS) and relapse-
free survival (RFS) were estimated by means of the product-
limit method (Kaplan & Meyer, 1958). Preliminary graphical
analyses suggested that the proportional hazard assumption
was not tenable; on the other hand, the plots of log (odds)
(probability of surviving/probability of dying) against log
(time) for all the categories ofprognostic variables resulted in
parallel straight lines. Therefore the role of each of the
prognostic variables (univariate analysis) and theirjoint effect
(multivariate analysis) were evaluated using a log-logistic
regression model (Bennett, 1983). This was shown to be
suitable for fitting breast cancer data accumulated from
previous reports (Gore et al., 1984). In the log-logistic
regression model each of the regression coefficients (p) is
recognisable as the log (odds ratio = OR) and is constant in
time (Bennett, 1983). For patients classified in two prognostic
categories and having the same survival experience, the statis-
Table II Association between EGFR and cell kinetics by Ki-67
immunostaining
EGFR Ki-67 score
low (<7.5%) high (>7.5%) Total
Negative 41(25%) 31(19%) 72
Positive 40 (24%) 52 (32%) 92
Total 81 83 164
K coefficient = 0.132.972 G. GASPARINI et al.
TableIII Distributionoftheclinico-pathologicalcharacteristicsaccordingto
the EGFR expression
EGFR
Feature Positive n (%) Negative n (%) X2 DF P
Overall 92 (56) 72 (44) - - -
Menopausal status
Premenopausal 25 (27) 22 (31)
Perimenopausal 10 (11) 4 (5) 1.52 2 0.467
Postmenopausal 57 (62) 46 (64)
Tumour size
pTl 49 (53) 44 (61)
pT2-3 43 (47) 28 (39) 1.01 1 0.314
Node status
negative 46 (50) 37 (51)
positive 46 (50) 35 (49) 0.03 1 0.860
Grading
I-II 46 (50) 40 (56)
III 46 (50) 32 (44) 0.50 1 0.480
Oestrogen receptor statusa
negative 38 (46) 29 (42)
positive 44 (54) 40 (58) 0.28 1 0.595
Progesterone receptor statusa
negative 44 (54) 42 (61)
positive 38 (46) 27 (39) 0.79 1 0.373
a14 pts had missing information about hormonal receptors DF = degrees of
freedom.
tic: exp(p) = 0 is expected to be 1.0. For OR<1 (OR> 1)
patients classified in a given category have an odds of surviv-
ing lower (greater) than that of patients in the reference
category. The hypothesis B = 0 was teted by Wald statistic
(Cox & Hinkley, 1974). For each variable, 'unadjusted' odds
ratios and their 95% confidence intervals were estimated
using the putative 'poorest prognosis' class as reference
category. To investigate the prognostic relevance of EGFR
allowing for the other prognostic variables the 'adjusted'
odds ratios were estimated using a multiple regression model
containing, besides EGFR, those variables which had un-
adjusted odds ratios significantly different from 1.0.
The impact of each prognostic factor on clinical outcome,
in addition to that of the remaining variables, was evaluated
by means of the likelihood ratio statistic.
Results
Immunocytochemical staining with the EGFRI monoclonal
antibody
EGFR1 antibody produced immunostaining labelling of
variable intensity and extent in the membrane of tumour cells
in 92 carcinomas (56%). Seventy-two tumours had only a
weak focal or failed to retain any convincing membrane
staining. This frequency of EGFR positivity is in accordance
with that previously found by our group (Bevilacqua et al.,
1990) and by others (Sainsbury et al., 1985). All slides
were independently evaluated by two investigators (P.B.;
S.M.).
Correlation ofEGFR to otherprognostic indicators
One hundred and forty-four of 164 tumours (88%) had
stained nuclei with GF scores varying from 1% to 80%
(median value = 7.5%) using the Ki-67 antibody. We
observed that EGFR-positive tumours had a slightly higher
GF score when compared to those EGFR-negative (K
coefficient = 0.132). The median average proportion of Ki-67
stained cells in EGFR-positive tumours was 10% compared
to 5% in the EGFR-negative ones. As shown in Table II, GF
was able to identify high proliferative activity within both
EGFR-positive and EGFR-negative tumours. As reported in
Table III the expression of EGFR was not significantly
associated with the other clinico-pathologic features analysed.
Clinical results
After a median follow-up of the patients of 36 months, the
overall 3-year probability of OS and RFS was 83% and
73%, respectively.
During the follow-up period 40 patients had recurrence of
disease. Thirty-three of them presented with distant metas-
tases, six developed metachronous breast carcinoma and one
had an isolated local relapse.
Twenty-four patients died, eight from causes unrelated to
breast carcinoma (included in the analysis).
Univariate analysis
Prognostic significance of the epidermal growth factor recep-
tor The survival analysis suggested that the EGFR pos-
itivity was significantly associated with recurrence. The 3-year
probability of RFS was 83% for patients with EGFR-
negative tumours (10/72 patients relapsed) compared to 65%
for patients with EGFR-positive tumours (30/92 patients
relapsed). EGFR-negative conferred a significantly lower
probability of relapse compared to the EGFR-positive ones
with an odds of not relapsing of 3.51 (X2 = 8.72, P = 0.003)
(Table IV) (Figure 1). The 3-year probability of OS was
similar in patients with EGFR-negative tumours compared to
the EGFR-positive ones (85% vs 81%) with an odds ratio of
1.09 (Table IV).
Prognostic Significance of the other factors In addition to
EGFR expression we investigated the prognostic importance
of GF using Ki-67 antibody, lymph node status, histologic
grade, pathologic tumour size and menopausal status.
We found that patients with low GF scores (<7.5%) had
a significantly lower probability of recurrence with an odds
of not relapsing of 3.51 (X2 = 8.98, P = 0.0027) compared to
those with high GFs (>7.5%) whereas patients with low GF
scores had only a slightly higher survival when compared to
those with high proliferating tumours (odds ratio of 1.79).
More details concerning the clinical results on GF have been
reported elsewhere (Gasparini et al., 1992a). When patients
were divided into four subsets on the basis of EGFR status
and GF score, the subset of patients with EGFR-positive
tumours and with high GF scores had the poorest 3-year
RFS rate whereas the subgroup of those with EGFR-
negative tumours and low GF scores had the best RFS
(Figure 2). Bivariate analysis showed that the differenceEPIDERMAL GROWTH FACTOR RECEPTOR AND PROGNOSIS IN BREAST CANCER 973
Table IV Univariate analysis of RFS and OS at 3 years
RFS OS
Unadjusted 95% confidence Wald Unadjusted 95% confidence Wald
Variable odds ratio interval statistic P odds ratio interval statistic P
EGFR
negative vs 3.51 (1.57-8.41) 8.72 0.0031 1.09 (0.42-2.92) 0.04 0.8430
positivea
Growth fraction
low vs 3.51 (1.59-8.20) 8.99 0.0027 1.79 (0.69-4.77) 1.57 0.2091
higha
Node status
negative vs 2.59 (1.21-5.76) 5.81 0.0159 2.79 (1.03-7.93) 4.06 0.0439
positivea
Grading
I-II vs 2.19 1.04-4.74) 4.21 0.0401 1.34 (0.53-3.46) 0.43 0.5135 ~Ila
Tumour size
pT, vs 1.53 (0.74-3.27) 1.38 0.2407 1.76 (0.71-4.67) 1.59 0.2078
pT2/3a
Menopausal status
postmenopausal vs 0.91 (0.39-2.11) 0.05 0.8237 0.63 (0.19-1.96) 0.72 0.3958
premenopausala
perimenopausal vs 0.44 (0.12-1.48) 1.81 0.1784 0.40 (0.07-2.11) 1.25 0.2625
premenopausala
OER
negativea vs 1.79 (0.81-3.99) 2.16 0.1418 0.68 (0.22-1.85) 0.63 0.4265
positive
PGR
negativea vs 0.90 (0.40-1.99) 0.07 0.7940 1.56 (0.51-4.78) 0.70 0.4000
positive
aReference category.
between subgroups reached significance (Table V). Patients
with poorly differentiated tumours had a significantly higher
frequency of recurrence (X2 = 4.21; P = 0.040), but the
difference did not reach significance concerning OS. Path-
ologic tumour size, menopausal status and steroid hormone
receptors did not significantly influence the outcome of
patients concerning both RFS and OS.
Finally, node status was the only factor that in the present
series significantly influenced both RFS and OS within 3-
years of surgery (Table IV).
Multivariate prognostic analysis
To evaluate the joint effect of the variables analysed, only the
terms relative to the main effects were inserted into the final
model as far as RFS was concerned. Since only node status
was significantly related with OS we did not perform a
multivariate analysis at this level.
GF, grading and node status were introduced first into the
model and EGFR was then added. A large increase
(likelihood ratio test, X2 = 9.12) was observed on introduc-
tion of EGFR. When GF was added to the model containing
a)
a)
16 I.-
Co
node status and EGFR a significant contribution of GF in
identifying patients with different risk was seen (likelihood
ratio test, x2= 5.81). Finally when grading was added to the
above variables, a non significant likelihood ratio test was
obtained (X2 = 0.96; P>0.05). This suggests that grading
gives no additional information on prognosis when the
patients are already classified by the other three factors
(Table VI). The contribution of node status was nearly
significant, when all the four variables were considered and
reached significance in a model that does not include grading
(likelihood ratio test x2 = 4.42; P = 0.035).
Discussion
Human breast cancer is a neoplasia characterised by a sub-
stantial heterogeneity, with various clones of cells ofdiffering
growth and metastatic potential (Dexter et al., 1978) which
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Figure 1 3-year probability of relapse-free survival (RFS) in
EGFR-positive (-
- -) and EGFR-negative ( ) patients.
Patients at risk at 3 years: EGFR-positive = 15; EGFR-
negative = 25.
Months
Figure 2 3-year probability of relapse-free survival (RFS) in the
four subsets of patients on the basis of the EGFR status and GF
score: EGFR-positive and high GF score (52 patients) ( --);
EGFR-negative and high GF score (31 patients (....); EGFR-
positive and low GF score (40 patients) ( ); and EGFR-
negative and low GF score (41 patients) (-). Patients at risk at
3-years: EGFR-positive and high GF =4; EGFR-negative and
high GF = 11; EGFR-positive and low GF = 8 and EGFR-
negative and low GF = 41.
1
k974 G. GASPARINI et al.
Table V Bivariate analysis of RFS at 3 years relative to: EGFR and
growth fraction
Adjusted 95% confidence Wald
Variable odds ratio interval statistic P
EGFR
negative vs 3.29 (1.45-8.02) 7.76 0.0053
positivea
Growth fraction
low vs higha 3.25 (1.46-8.20) 7.91 0.0049
aReference category.
Table VI Multivariate analysis ofRFS at 3 years relative to: EGFR, growth fraction, node status and
grading
Adjusted 95% confidence Wald Likelihood
Variable odds ratio interval statistic P ratio test P
EGFR
negative vs 3.36 (1.47-8.26) 7.90 0.0049 9.12 0.0025
positivea
Growth fraction
low vs higha 2.65 (1.16-6.35) 5.26 0.0219 5.81 0.0160
Node status
negative vs 2.10 (0.93-4.84) 3.28 0.0701 3.50 0.0612
positivea
Grading
I-II vs 1.47 (0.66-3.36) 0.94 0.3309 0.96 0.3261
IIIa
aReference category.
provides a dilemma for treatment. For this reason
identification of new markers related to tumour aggres-
siveness has been sought to better predict both clinical out-
come of patients and response to therapy (McGuire, 1987).
A large body of experimental studies suggest that among
the new biological indicators of tumour aggressiveness, the
overexpression of EGFR has an important place in the pro-
gression of breast cancer, being involved in the autocrine
mechanisms of tumour cell growth (Fitzpatrick et al., 1984;
Salomon et al., 1984; Lippman et al., 1986). However, con-
troversy exists in the literature concerning the relationship
between EGFR expression with both known prognostic fac-
tors and new emerging biological markers (i.e. oncogene
expression, cell kinetics,...) as well as prognosis in human
breast carcinoma.
Firstly it is not clear which is the optimum method of
EGFR detection in human pathological material. The most
widely used method is the ligand binding assay which gives a
good quantification of the receptor expression level but is
time-consuming, requires bulk frozen tissue and needs to be
standardised (Koenders et al., 1991). The recent generation
of monoclonal antibodies to EGFR has permitted the
development of immunocytochemical assays. These latter
present potential advantages, mainly the possibility to dis-
criminate between the neoplastic and normal cell component
of the tissues and the ability to detect the intratumoural
heterogeneity of EGFR expression. These are easier to per-
form, are rapid, have low costs and finally, require smaller
samples when compared to the biochemical methods. How-
ever, at present, little is known about the correlation between
the biochemical and the immunocytochemical assays concer-
ning the detection of EGFR. Data from Sainsbury et al.
(unpublished) show a concordance between the two of about
80% in breast tumours and Neal et al. (1985) found a strong
correlation in bladder cancer. Further studies are thus
required to assess this question.
In the present study we assessed EGFR using the EGFR-1
monoclonal antibody and an immunocytochemical method,
and found that 56% of primary breast carcinomas had mem-
brane staining and were classified as EGFR-positive tumours.
This frequency of EGFR-positivity is in the range of those
reported by others adopting either radioligand or
immunocytochemical assays (22% to 67%) (see Koenders et
al., 1991 for a review). The association of EGFR with the
conventional clinico-pathological features is still controversial
and also needs further investigation. In our series we did not
find a significant association of EGFR with lymph-node
status, tumour size or differentiation grade. This is in agree-
ment with observations of Pekonen et al. (1988) and
Koenders et al. (1991). As regards EGFR, significant rela-
tionship with nodal status has been reported (Sainsbury et
al., 1987; Macias et al., 1987) but, as in this present study,
was not found by others (Sainsbury et al., 1985; Toi et al.,
1991). Controversy also exists regarding the association of
EGFR with tumour size and grading (Walker & Camplejohn,
1986; Lewis et al., 1990).
Moreover, in the present study we did not observe a
correlation of EGFR with steroid hormone receptor and this
is in agreement with some other studies (Fitzpatrick et al.,
1984; Peyrat et al., 1984; Bevilacqua et al., 1990) but in
disagreement with the majority of authors who reported a
significant inverse relationship between EGFR expression
and ER-positivity (Koenders et al., 1991; Sainsbury et al.,
1987; Lewis et al., 1990; Spyratos et al., 1990).
There is also conflicting data in the literature regarding the
relationship between EGFR and cell kinetics parameters in
human breast carcinoma (Walker & Camplejohn, 1986; Gas-
parini et al., 1991). Therefore, to analyse this latter point we
measured cell kinetics using the Ki-67 monoclonal antibody.
We observed that EGFR-positive tumours more often had
high Ki-67 scores (32%) when compared to those EGFR-
negative ones (19%), however, the overall agreement between
the two variables was poor (K = 0.132). In other studies we
also found a lack ofassociation between EGFR and c-erbB-2
oncoprotein (Gasparini et al., 1992b) and neo-vascularisation
(i.e. tumour angiogenesis) (Gasparini et al., 1992c).
Thus, in our experience, the overall picture is that EGFR
status seems to be independent not only from the conven-
tional pathologic parameters but also from some of the new
biological markers of prognosis with emerging importance in
human breast cancer. Finally, there are also contradictory
findings concerning the correlation of EGFR expression and
outcome of patients with early-stage breast carcinoma. In
fact, some clinical studies confirmed this association (Sains-
bury et al., 1987; Macias et al., 1987; Wright et al., 1989; Toi
et al., 1991; Nicholson et al., 1991) whereas others found noEPIDERMAL GROWTH FACTOR RECEPTOR AND PROGNOSIS IN BREAST CANCER 975
such correlation (Foekens et al., 1989; Spyratos et al., 1990).
In our series EGFR status is a significant prognostic factor
for recurrence, but not for overall survival when evaluated by
univariate analysis.
These discrepancies regarding the prognostic role of EGFR
in human breast cancer may in part be attributed to the
different techniques used to assay this receptor, to different
patient characteristics and to the different length of follow-
up. Adjuvant therapy for patients at high risk of recurrence
may also affect the relationship.
We observed that cell kinetics, grading and lymph-nodes
status were also significant predictors of relapse-free survival
on univariate analysis. When a multivariate logistic model
was used to evaluate the joint effect of the variables, we
found that EGFR, growth fraction and node status retained
their prognostic importance, whereas histological grade gave
no additional information on the probability of relapse.
Node status was the only significant prognostic factor for
overall survival in our series. The growth fraction score was
able to identify subgroups of patients with known EGFR
status at different risk of recurrences. The EGFR-negative
and low GFs tumours had the better prognosis, the EGFR-
positive and high GFs ones had the least favourable outcome
and discordant subgroups had an intermediate prognosis.
These differences reached significance for RFS (Table V).
An overview of our experience involving EGFR with
multivariate analysis, applied in different settings and with
various variables in operable breast cancer, shows that it is a
significant and independent prognostic factor for RFS when
evaluated with conventional pathological features and growth
fraction. In contrast EGFR fails to retain a significant prog-
nostic importance when tested with c-erbB-2 oncoprotein and
DNA ploidy (Gasparini et al., 1992b) and/or with tumour
angiogenesis (Gasparini et al., 1992c).
In conclusion, present results indicate that EGFR expres-
sion is an important indicator of recurrence in stage I-II
breast cancer. The simultaneous determination ofcell kinetics
allows for a better identification of patients at different risks,
with easy and reliable in situ immunocytochemical assays.
This observation must be confirmed in larger series and in
studies with a longer follow-up so as to also better evaluate
its impact on overall survival.
The recent demonstration that the administration of radio-
labelled monoclonal antibodies against EGFR may give
therapeutic benefits (Kalafonos et al., 1989), potentially paves
the way for promising new therapeutic approaches.
We believe that EGFR and GF score could be considered
as additional factors in improving the selection of patients
with different outcomes. It may provide a rationale for better
identification of patients in the poorer prognosis sub-group
who might be offered systemic adjuvant treatments.
The authors thank Daniela Mazzocco for assistance in the prepara-
tion of the manuscript.
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